The 482 study was an international, Phase III, randomized, double-blind, multicenter trial of Xgeva (denosumab)compared with zoledronic acid in the...
Amgen has announced findings from a randomised, double-blind, double-dummy, multicentre Phase IV study showing that Prolia (denosumab) achieved greater gains...
In a phase III study of Zgeva(denosumab), men with castration-resistant prostate cancer and no previous exposure to intravenous bisphosphonate drugs...
Treatment with Xgeva (denosumab), from Amgen, resulted in a greater reduction in skeletal-related events in patients with Breast Cancer that...
- Prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone. - Treatment of adult patients with tumour-induced hypercalcaemia (TIH).